中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Menu
Issue 7
Jul.  2011
Turn off MathJax
Article Contents
Abstract
References
Article Navigation >  Journal of Clinical Hepatology  > 2011  >  27(7): 726-728

Analysis of clinical characteristics of 150 cases of pediatric hepatitis caused by nonhepatotropic pathogen

  • Published Date: 2011-07-20
    Abstract
  • Objective To study the clinical characteristics of pediatric hepatitis caused by nonhepatotropic pathogen.Methods Retrospective analysis of the clinical characteristics of 150 cases diagnosed with non-hepatotropic pathogen related hepatitis in pediatric gastroenterology department, Shengjing hospital during Jan, 2009 to Sept, 2010 were studied.Results There were 81 males and 69 females in the 150 cases.Mycoplasma pneumoniae and EB virus were the main causes of the non-hepatotropic pathogen related hepatitis, with 69 cases (46%) and 59 cases (39.33%) respectively.Compared with pre-treatment, there were significant reduction in the level of ALT and AST (P<0.05) after treatment.Conclusion The results show that the clinical manifestations of non-hepatotropic pathogen related hepatitis are nonspecific.ALT and AST can be used to confirm the diagnosis.Early diagnosis and treatment are the key points to improve the prognosis.

     

    • FullText(HTML)

  • 在肝细胞癌(HCC)的治疗中，放射治疗日益成为一种重要的治疗策略。然而，对放射治疗的抵抗是成功治疗的主要障碍之一。因此，该研究旨在阐明放射抵抗的机制，并寻找可靠的生物靶点，以提高HCC放射治疗的疗效。

    从无标记的定量蛋白质组筛选中，确定转移RNA(tRNA；鸟嘌呤-N[7]-)甲基转移酶1(METTL1)是N7-甲基鸟苷(M7G)tRNA修饰的关键酶，是HCC细胞辐射抗性的重要驱动因素。通过体外和体内功能丧失及功能获得实验分析，发现METTL1促进DNA双链断裂(DSB)修复，并使HCC细胞对电离辐射产生抵抗。

    在机制上，METTL1介导的M7G tRNA修饰选择性地调节电离辐射处理后DNA依赖的蛋白激酶催化亚基或DNA连接酶Ⅳ的翻译，从而导致非同源末端连接(NHEJ)介导的DNA DSB修复效率提高。临床上，肿瘤组织中METTL1的高表达与接受放射治疗的HCC患者的不良预后显著相关。

    研究表明，METTL1是电离辐射治疗后HCC细胞基于NHEJ的DNA修复的关键增强剂。这些发现有助于了解tRNA修饰在信使RNA翻译控制中的作用。

    摘译自LIAO J, YI Y, YUE X, et al. Methyltransferase 1 is required for nonhomologous end-joining repair and renders hepatocellular carcinoma resistant to radiotherapy[J]. Hepatology, 2022. DOI: 10.1002/hep.32615. [Online ahead of print]

    (吉林大学第一医院感染病中心肝病科  韩雨金  金清龙  报道)

    • References(17)
  • [1]蔡莹, 周晓霞, 方静, 等.86例小儿非嗜肝病毒感染所致肝功能损害的临床分析[J].中国当代儿科杂志, 2009, 11 (2) :148-150.
    [2]Principi N, Esposito S.Mycoplasma pneumonia and Chlamydiapneumonia cause lower respiratory tract disease in paediatricpatients[J].Curr Opin Infect Dis, 2002, 15 (4) :295.
    [3]张晓波, 王立波, 张灵恩, 等.儿童肺炎支原体感染肺外脏器受累56例临床分析[J].临床儿科杂志, 2003, 21 (6) :344-346.
    [4]汤文红, 曹秀章.小儿呼吸道肺炎支原体感染发病趋势及临床分析[J].临床儿科杂志, 2005, 23 (8) :562-563.
    [5]宋顺琪, 吴茜, 倪林仙, 等.小儿肺炎支原体、嗜肺军团菌并肝损伤15例分析[J].中国实用医药, 2010, 5 (22) :183.
    [6]Feigin RD, Cherry DJ.Testbook of pediatric infectious diseases[M].5th ed.Pennsylvania:W.B.Saunders, 2004:2516-2547.
    [7]Hammerschlag M.Mycoplasma pneumoniae infections[J].CurrOpin Infect Dis, 2001, 14 (2) :181-186.
    [8]Daxboeck F, Gattringer R, Mustafa S, et al.Elevated serum alanineaminotransferase (ALT) levels in patients with serologically verifiedMycoplasma pneumoniae pneumonia[J].Clin Microbiol Infect, 2005, 11 (6) :507-510.
    [9]Smets F, Latinne D, Bazin H, et al.Ratio between Epstein-Barr viralload and anti-Epstein-Barr virus specific T cell response as apredictive marker of posttransplant lymphoproliferative disease[J].Transplantation, 2002, 73 (10) :1603-1610.
    [10]Kimura H, Nagasaka T, Hoshino Y, et al.Severe hepatitis causedby Epstein-Barr virus without infection of hepatocytes[J].HumPathol, 2001, 32 (7) :757-762.
    [11]孙雪荣, 陈佳红, 于春, 等.EB病毒感染与婴儿肝炎综合征的临床研究[J].中国全科医学, 2008, 11 (8) :652-653, 657.
    [12]Macsween KF, Crawford DH.Epstein-Barr virus recentadvances[J].Lancet Infect Dis, 2003, 3 (3) :131-140.
    [13]Shibuya A, Tsuchihashi T, Watanabe M, et al.Severe chronic activeEpstein-Barr virus infection associated with multiple necroticlesions in the liver[J].Hepatol Res, 2003, 25 (4) :447-454.
    [14]Wang J, Atchison RW, Walpusk J, et al.Echo virus hepaticfailure in infancy:report of four cases with speculation on thepathogenesis[J].Pediatr Dev Pathol, 2001, 4 (5) :454-460.
    [15]周智, 赖宁, 王明桃, 等.68例非嗜肝病毒所致肝炎患者病因学分析及其临床特点[J].中华肝脏病杂志, 2004, 12 (3) :130.
    [16]白淑霞, 付宇, 李文芳, 等.EB病毒感染致严重肝损害死亡2例分析[J].中国误诊学杂志, 2010, 10 (1) :220-221.
    [17]高建兴, 黄莹.慢性活动性EB病毒感染致肝硬化1例[J].现代中西医结合杂志, 2009, 18 (30) :3758-3759.
    • Relative Articles

  • Relative Articles

    [1]Shaoxuan LUO, Ya LI, Feng XU. A case of hepatolenticular degeneration with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(5): 1119-1121. doi: 10.3969/j.issn.1001-5256.2022.05.028
    [2]Xiaoqiang GAO, Shi ZUO, Xiaodong JIA, Yinying LU. Association between mitochondrial dysfunction and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2022, 38(6): 1436-1439. doi: 10.3969/j.issn.1001-5256.2022.06.045
    [3]General Office of National Health Commission. Standard for diagnosis and treatment of primary liver cancer (2022 edition)[J]. Journal of Clinical Hepatology, 2022, 38(2): 288-303. doi: 10.3969/j.issn.1001-5256.2022.02.009
    [4]Zhao LI, Jiye ZHU. Interpretation of Standard for diagnosis and treatment of primary liver cancer (2022 edition)[J]. Journal of Clinical Hepatology, 2022, 38(5): 1027-1029. doi: 10.3969/j.issn.1001-5256.2022.05.010
    [5]General Office of National Health Commission. Standard for diagnosis and treatment of pancreatic cancer (2022 edition)[J]. Journal of Clinical Hepatology, 2022, 38(5): 1006-1015. doi: 10.3969/j.issn.1001-5256.2022.05.007
    [6]Liangqing DONG, Qiang GAO. Multi-omics molecular subgrouping of hepatocellular carcinoma and its application in precision diagnosis and treatment[J]. Journal of Clinical Hepatology, 2022, 38(3): 510-514. doi: 10.3969/j.issn.1001-5256.2022.03.004
    [7]Qiang ZOU, Jun WANG, Liangzhi WEN, Bin WANG, Yi ZHANG. Molecular heterogeneity of hepatocellular carcinoma and its precise treatment in clinical practice[J]. Journal of Clinical Hepatology, 2021, 37(8): 1765-1769. doi: 10.3969/j.issn.1001-5256.2021.08.006
    [8]Liangzhi WEN, Xiao XIAO, Qixian YAN, Jun WANG. Advances in clinical research on vascular interventional therapy for hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2021, 37(8): 1761-1764. doi: 10.3969/j.issn.1001-5256.2021.08.005
    [9]Precise Radiotherapy Study Group, Chinese Society of Liver Cancer, Chinese Medical Doctor Association, Liver Cancer Study Group, Committee of Radiation Oncology, Chinese Research Hospital Association, Committee of Tumor Radiobiology and Multimodal Imaging and Therapy, Chinese Research Hospital Association, Liver Cancer Study Group, Precise Radiotherapy Branch, Chinese Society of Biomedical Engineering. Consensus on radiation therapy for primary liver cancer (2020)[J]. Journal of Clinical Hepatology, 2021, 37(2): 296-301. doi: 10.3969/j.issn.1001-5256.2021.02.010
    [10]Gang REN, Yingjie WANG. Advances in radiotherapy for pancreatic cancer from 2019 to 2020[J]. Journal of Clinical Hepatology, 2021, 37(3): 733-736. doi: 10.3969/j.issn.1001-5256.2021.03.048
    [11]Yuan ShengXian, Zhou WeiPing. Conversion therapy for hepatocellular carcinoma: Strategies and methods[J]. Journal of Clinical Hepatology, 2020, 36(2): 252-257. doi: 10.3969/j.issn.1001-5256.2020.02.002
    [12]Bureau of Medical Administration, National Health Commission of the People’s Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. Journal of Clinical Hepatology, 2020, 36(2): 277-292. doi: 10.3969/j.issn.1001-5256.2020.02.007
    [13]Wang Shan, Wu QingWang, Li XiaoKe, Ye YongAn. Interpretation of Guidelines for diagnosis and treatment of primary liver cancer in China (2019edition)[J]. Journal of Clinical Hepatology, 2020, 36(5): 996-999. doi: 10.3969/j.issn.1001-5256.2020.05.009
    [14]Liu YueChen, Gu MengYu, Cheng Yu, Yang GuiYuan. An excerpt of radiation therapy for pancreatic cancer: Executive summary of an ASTRO clinical practice guideline (2019)[J]. Journal of Clinical Hepatology, 2020, 36(1): 50-52. doi: 10.3969/j.issn.1001-5256.2020.01.010
    [15]Compilation and Examination Expert Group for Guidelines for the diagnosis and treatment of hepatoblastoma (2019). Guidelines for the diagnosis and treatment of hepatoblastoma (2019)[J]. Journal of Clinical Hepatology, 2019, 35(11): 2431-2434. doi: 10.3969/j.issn.1001-5256.2019.11.008
    [16]Li ShanShan, Chen Yu. Severe radiation-induced gastritis after radiotherapy for hepatocellular carcinoma: A case report[J]. Journal of Clinical Hepatology, 2019, 35(9): 2048-2049. doi: 10.3969/j.issn.1001-5256.2019.09.033
    [17]Li TianTian, Sun Jing, Wang Quan, Ding JunQiang, Wang Jia, Xue Hui, Zhang Tao, Duan XueZhang. Clinical effect of stereotactic body radiotherapy in treatment of patients with small hepatocellular carcinoma and related prognostic factors[J]. Journal of Clinical Hepatology, 2018, 34(8): 1702-1706. doi: 10.3969/j.issn.1001-5256.2018.08.022
    [18]Fang ZiYan, Huang Long, Li Gong. Research progress in radiotherapy for liver tumors reported in 2013 ASTRO Annual Meeting[J]. Journal of Clinical Hepatology, 2014, 30(4): 383-385. doi: 10.3969/j.issn.1001-5256.2014.04.025
    [19]Ren Gang, Wang Jing, Xia TingYi. Interpretation of radiotherapy document in Chinese expert consensus on comprehensive diagnosis and treatment of pancreatic cancer (2014 Edition)[J]. Journal of Clinical Hepatology, 2014, 30(12): 1249-1252. doi: 10.3969/j.issn.1001-5256.2014.12.005
    [20]Guo ZhanWen, Li Yu, Yan Ying, Tian QiHe, Xu Rui. Clinical study of 3-dimensional conformal radiotherapy on primary liver cancer.[J]. Journal of Clinical Hepatology, 2002, 18(3): 164-165.
    • Supplements(0)
    • Cited By
  • 加载中
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 41.3 %FULLTEXT: 41.3 %META: 37.5 %META: 37.5 %PDF: 21.2 %PDF: 21.2 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 3.1 %其他: 3.1 %其他: 0.7 %其他: 0.7 %Central District: 0.2 %Central District: 0.2 %China: 2.2 %China: 2.2 %Hawthorne: 0.0 %Hawthorne: 0.0 %India: 0.1 %India: 0.1 %North Point: 0.0 %North Point: 0.0 %Seattle: 0.0 %Seattle: 0.0 %United States: 0.2 %United States: 0.2 %[]: 0.5 %[]: 0.5 %上海: 6.2 %上海: 6.2 %上饶: 0.1 %上饶: 0.1 %东京: 0.1 %东京: 0.1 %东京都: 0.1 %东京都: 0.1 %东方: 0.0 %东方: 0.0 %东莞: 0.6 %东莞: 0.6 %东营: 0.1 %东营: 0.1 %中卫: 0.4 %中卫: 0.4 %临汾: 0.2 %临汾: 0.2 %临沂: 0.0 %临沂: 0.0 %丽水: 0.1 %丽水: 0.1 %乌海: 0.0 %乌海: 0.0 %乌鲁木齐: 0.2 %乌鲁木齐: 0.2 %休斯敦: 0.0 %休斯敦: 0.0 %佛山: 0.6 %佛山: 0.6 %佛罗里达州: 0.0 %佛罗里达州: 0.0 %保定: 0.3 %保定: 0.3 %克卢日-纳波卡: 0.0 %克卢日-纳波卡: 0.0 %六安: 0.1 %六安: 0.1 %六盘水: 0.0 %六盘水: 0.0 %兰州: 0.2 %兰州: 0.2 %内江: 0.1 %内江: 0.1 %加利福尼亚: 0.2 %加利福尼亚: 0.2 %北京: 8.1 %北京: 8.1 %北海: 0.1 %北海: 0.1 %南京: 1.9 %南京: 1.9 %南宁: 1.2 %南宁: 1.2 %南昌: 0.1 %南昌: 0.1 %南阳: 0.0 %南阳: 0.0 %厦门: 0.3 %厦门: 0.3 %台州: 0.0 %台州: 0.0 %合肥: 0.6 %合肥: 0.6 %吉林: 1.0 %吉林: 1.0 %周口: 0.1 %周口: 0.1 %呼和浩特: 0.1 %呼和浩特: 0.1 %咸宁: 0.2 %咸宁: 0.2 %哈尔滨: 0.6 %哈尔滨: 0.6 %哈尔科夫: 0.1 %哈尔科夫: 0.1 %哥伦布: 0.0 %哥伦布: 0.0 %唐山: 0.2 %唐山: 0.2 %商丘: 0.2 %商丘: 0.2 %嘉兴: 0.0 %嘉兴: 0.0 %圣保罗: 0.1 %圣保罗: 0.1 %墨尔本: 0.2 %墨尔本: 0.2 %多伦多: 0.0 %多伦多: 0.0 %大连: 0.1 %大连: 0.1 %天水: 0.1 %天水: 0.1 %天津: 0.9 %天津: 0.9 %太原: 0.7 %太原: 0.7 %威海: 0.1 %威海: 0.1 %娄底: 0.0 %娄底: 0.0 %安康: 0.1 %安康: 0.1 %宝鸡: 0.0 %宝鸡: 0.0 %宣城: 0.2 %宣城: 0.2 %密蘇里城: 0.1 %密蘇里城: 0.1 %崇左: 0.1 %崇左: 0.1 %巴黎: 0.1 %巴黎: 0.1 %常州: 0.0 %常州: 0.0 %常德: 0.2 %常德: 0.2 %平顶山: 0.0 %平顶山: 0.0 %广元: 0.0 %广元: 0.0 %广安: 0.1 %广安: 0.1 %广州: 2.3 %广州: 2.3 %廊坊: 0.3 %廊坊: 0.3 %开封: 0.0 %开封: 0.0 %张家口: 2.0 %张家口: 2.0 %徐州: 0.2 %徐州: 0.2 %德州: 0.1 %德州: 0.1 %怀化: 0.1 %怀化: 0.1 %惠州: 0.1 %惠州: 0.1 %意法半: 0.0 %意法半: 0.0 %成都: 0.8 %成都: 0.8 %扬州: 0.1 %扬州: 0.1 %揭阳: 0.2 %揭阳: 0.2 %新乡: 0.1 %新乡: 0.1 %新奥尔良: 0.0 %新奥尔良: 0.0 %无锡: 0.4 %无锡: 0.4 %昆明: 1.1 %昆明: 1.1 %昌吉: 0.0 %昌吉: 0.0 %晋城: 0.0 %晋城: 0.0 %普洱: 0.0 %普洱: 0.0 %朝阳: 0.0 %朝阳: 0.0 %杭州: 1.2 %杭州: 1.2 %枣庄: 0.1 %枣庄: 0.1 %柳州: 0.2 %柳州: 0.2 %桂林: 0.2 %桂林: 0.2 %梧州: 0.0 %梧州: 0.0 %榆林: 0.1 %榆林: 0.1 %武汉: 1.8 %武汉: 1.8 %氹仔: 0.1 %氹仔: 0.1 %汕头: 0.4 %汕头: 0.4 %江门: 0.2 %江门: 0.2 %沈阳: 0.4 %沈阳: 0.4 %河池: 0.1 %河池: 0.1 %泉州: 0.1 %泉州: 0.1 %泰安: 0.1 %泰安: 0.1 %泰州: 0.1 %泰州: 0.1 %泸州: 0.2 %泸州: 0.2 %洛阳: 0.2 %洛阳: 0.2 %济南: 0.9 %济南: 0.9 %济宁: 0.1 %济宁: 0.1 %海口: 0.0 %海口: 0.0 %海得拉巴: 0.1 %海得拉巴: 0.1 %淄博: 0.1 %淄博: 0.1 %淮安: 0.2 %淮安: 0.2 %深圳: 1.2 %深圳: 1.2 %温州: 0.3 %温州: 0.3 %湘潭: 0.1 %湘潭: 0.1 %湛江: 0.4 %湛江: 0.4 %滨州: 0.0 %滨州: 0.0 %漯河: 0.2 %漯河: 0.2 %漳州: 0.0 %漳州: 0.0 %潍坊: 0.5 %潍坊: 0.5 %潮州: 0.1 %潮州: 0.1 %澳门: 0.2 %澳门: 0.2 %濮阳: 0.0 %濮阳: 0.0 %烟台: 0.1 %烟台: 0.1 %焦作: 0.0 %焦作: 0.0 %玉林: 0.2 %玉林: 0.2 %珠海: 0.0 %珠海: 0.0 %盐城: 0.0 %盐城: 0.0 %眉山: 0.0 %眉山: 0.0 %石家庄: 1.8 %石家庄: 1.8 %福州: 0.8 %福州: 0.8 %绍兴: 0.1 %绍兴: 0.1 %绵阳: 0.2 %绵阳: 0.2 %美国伊利诺斯芝加哥: 0.0 %美国伊利诺斯芝加哥: 0.0 %聊城: 0.1 %聊城: 0.1 %舟山: 0.1 %舟山: 0.1 %芒廷维尤: 24.5 %芒廷维尤: 24.5 %芝加哥: 0.3 %芝加哥: 0.3 %苏州: 0.9 %苏州: 0.9 %荆州: 0.0 %荆州: 0.0 %荆门: 0.1 %荆门: 0.1 %莆田: 0.1 %莆田: 0.1 %莫斯科: 0.1 %莫斯科: 0.1 %菏泽: 0.0 %菏泽: 0.0 %萍乡: 0.3 %萍乡: 0.3 %葫芦岛: 0.1 %葫芦岛: 0.1 %蚌埠: 0.0 %蚌埠: 0.0 %衡水: 0.1 %衡水: 0.1 %衡阳: 0.1 %衡阳: 0.1 %襄阳: 0.0 %襄阳: 0.0 %西宁: 6.2 %西宁: 6.2 %西安: 1.0 %西安: 1.0 %西雅图: 0.0 %西雅图: 0.0 %许昌: 0.0 %许昌: 0.0 %诺沃克: 0.0 %诺沃克: 0.0 %贵阳: 0.1 %贵阳: 0.1 %贺州: 0.1 %贺州: 0.1 %资阳: 0.0 %资阳: 0.0 %赣州: 0.2 %赣州: 0.2 %赤峰: 0.0 %赤峰: 0.0 %运城: 0.5 %运城: 0.5 %遂宁: 0.0 %遂宁: 0.0 %遂宁市船山区: 0.0 %遂宁市船山区: 0.0 %遵义: 0.2 %遵义: 0.2 %邯郸: 0.0 %邯郸: 0.0 %郑州: 1.0 %郑州: 1.0 %郴州: 0.0 %郴州: 0.0 %鄂州: 0.1 %鄂州: 0.1 %重庆: 0.7 %重庆: 0.7 %金奈: 0.2 %金奈: 0.2 %钦州: 0.2 %钦州: 0.2 %银川: 0.2 %银川: 0.2 %镇江: 0.1 %镇江: 0.1 %长春: 2.1 %长春: 2.1 %长沙: 1.6 %长沙: 1.6 %长治: 0.0 %长治: 0.0 %阳江: 0.1 %阳江: 0.1 %阿坝: 0.0 %阿坝: 0.0 %雅安: 0.1 %雅安: 0.1 %青岛: 0.9 %青岛: 0.9 %香港特别行政区: 0.0 %香港特别行政区: 0.0 %马尼拉: 0.1 %马尼拉: 0.1 %马鞍山: 0.1 %马鞍山: 0.1 %驻马店: 0.0 %驻马店: 0.0 %鸡西: 0.0 %鸡西: 0.0 %黄冈: 0.2 %黄冈: 0.2 %黄石: 0.2 %黄石: 0.2 %龙岩: 0.0 %龙岩: 0.0 %其他其他Central DistrictChinaHawthorneIndiaNorth PointSeattleUnited States[]上海上饶东京东京都东方东莞东营中卫临汾临沂丽水乌海乌鲁木齐休斯敦佛山佛罗里达州保定克卢日-纳波卡六安六盘水兰州内江加利福尼亚北京北海南京南宁南昌南阳厦门台州合肥吉林周口呼和浩特咸宁哈尔滨哈尔科夫哥伦布唐山商丘嘉兴圣保罗墨尔本多伦多大连天水天津太原威海娄底安康宝鸡宣城密蘇里城崇左巴黎常州常德平顶山广元广安广州廊坊开封张家口徐州德州怀化惠州意法半成都扬州揭阳新乡新奥尔良无锡昆明昌吉晋城普洱朝阳杭州枣庄柳州桂林梧州榆林武汉氹仔汕头江门沈阳河池泉州泰安泰州泸州洛阳济南济宁海口海得拉巴淄博淮安深圳温州湘潭湛江滨州漯河漳州潍坊潮州澳门濮阳烟台焦作玉林珠海盐城眉山石家庄福州绍兴绵阳美国伊利诺斯芝加哥聊城舟山芒廷维尤芝加哥苏州荆州荆门莆田莫斯科菏泽萍乡葫芦岛蚌埠衡水衡阳襄阳西宁西安西雅图许昌诺沃克贵阳贺州资阳赣州赤峰运城遂宁遂宁市船山区遵义邯郸郑州郴州鄂州重庆金奈钦州银川镇江长春长沙长治阳江阿坝雅安青岛香港特别行政区马尼拉马鞍山驻马店鸡西黄冈黄石龙岩

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索
    Get Citation
    PDF
    XML

    Article Metrics

    Article views (310) PDF downloads(107) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[1964]YesterdayPV[4402]TodayIP[2419]TodayPV[4946]Online[47]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return